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Abstract  
The ubiquitin-proteasome offers novel targets for potential therapies with their specific activities 
and tissue localization. Recently, the expansion of our understanding of how ubiquitin ligases 
(E3s) specifically regulate transcription has demonstrated their roles in skeletal muscle, 
complementing their roles in protein quality control and protein degradation. This review focuses 
on skeletal muscle E3s that regulate transcription factors critical to myogenesis and the 
maintenance of skeletal muscle wasting diseases. (Word count=68) 
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Non-standard abbreviations: C/EBPβ, CCAAT/Enhancer-binding protein β; COPD, Chronic 
obstructive pulmonary disease; HUWE1, HECT, UBA And WWE Domain Containing 1, E3 
Ubiquitin Protein Ligase; Itch, Itchy E3 Ubiquitin Protein Ligase, aka AIP4 (Atrophin-1 
Interacting Protein 4); LPS, Lipopolysaccharide, MDM2, Mouse double minute 2 homolog; 
MRF, Muscle regulatory transcription factor; MYOD, Myogenic differentiation antigen; 
NEDD4, Neural precursor cell-expressed developmentally downregulated gene 4; NEMO: NF-
κB essential modulator; NF-κB, Nuclear factor kappa-light-chain-enhancer of activated B cells; 
PAX7, Paired box 7; PIC, Pre-Initiation complex; RBP-Jκ; Recombination Signal Binding 
Protein For Immunoglobulin Kappa J Region; RING, Really interesting new gene; TAF, TATA-
box binding protein-associated factors; TBP, TATA-box binding protein; TFIID, Transcription 
factor IID; TRIP12, Thyroid Hormone Receptor Interactor 12; TRAF7, TNF Receptor 
Associated Factor 7; Ub, ubiquitin; UPF1, Up-Frameshift Suppressor 1 Homolog; UPS, 
Ubiquitin protease system; USP10, Ubiquitin Specific Peptidase 10  
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Introduction 
 
Skeletal muscle homeostasis is not only essential for day-to-day activities but also the healthy 
functioning of the body. Alterations in skeletal muscle strength and function are concomitant 
with several other disease pathophysiologies including diabetes, COPD, Duchenne muscular 
dystrophy, motor neuron diseases (55). The reduction in muscle mass, recognized commonly as 
muscle wasting or atrophy, results in loss of muscle function and is associated with increased 
morbidity and mortality (1). It occurs due to various physiological and pathological 
consequences. One of the most prevalent physiological causes of atrophy is aging and termed as 
sarcopenia (62), which involves several molecular, functional and histological changes in the 
muscle leading to frailty and functional decline in older adults. The pathological causes of 
atrophy include cancer cachexia, burns, chronic heart failure, chronic kidney disease, AIDS, 
mechanical ventilation, chronic obstructive pulmonary disorder (COPD), sepsis, immune 
disorders, dystrophies, etc. which all contribute to muscle atrophy in unique ways (13). 
 
The regenerative capabilities of skeletal muscle in case of injury or damage is remarkable and is 
enabled by the presence of tissue-specific adult stem cells, termed as satellite cells which are 
located between the basal lamina and sarcolemma of the muscle fibers (Figure 1) (28). 
Inherently quiescent, satellite cells get activated by stimulus in response to injury, stretching, 
exercise, and denervation among other pathological states such as myositis, muscular dystrophy, 
genetic mutations and cancer cachexia, for example (11, 32, 44, 61). Quiescent satellite cells 
have a number of fates, including division to renew themselves and asymmetric division to both 
renew themselves and produce cells capable of differentiating (Figure 1A). Within the broader 
population of satellite cells, SCs can both divide asymmetrically and exist in asymmetric 
populations, some of which only differentiate into myocytes and do not self-renew (Figure 1B). 
In this review, we focus on these quiescent SC cells, which are Pax7 expressing (Figure 1C-1G). 
Quiescent SCs express the transcription factor paired box 7 (PAX7) (Figure 1C), whereas 
activated SCs co-express PAX7 and muscle regulatory transcription factors MyoD, Myf5 and 
drive the proliferation of these cells (termed myoblasts) (Figure 1D) (70). On the other hand, the 
activated SCs can also go back to quiescence state by losing MyoD to maintain the progenitor 
pool (Figure 1E). The myoblasts after few rounds of proliferation start to differentiate by losing 
PAX7 and expressing muscle regulatory transcription factor myogenin (Figure 1F). These 
mature myoblasts fuse to form the differentiated regenerated myofibers (Figure 1G)(58). These 
myofibers also express transcription factors like p53 and MyoD whose specific function is 
unknown and may be related to the maintenance of neuro-muscular junction support (36, 69). 
 
Muscle atrophy is the balance between protein synthesis and protein degradation, both of which 
regulate protein turn over (10). Autophagy-lysosome and ubiquitin-proteasome systems are the 
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two major cell proteolytic systems that regulate the enhanced protein degradation in myocyte 
atrophy. While the ubiquitin proteasome system (UPS) is primarily attributed to the protein 
degradation of sarcomere proteins in atrophy, its role in regulating transcription factors 
governing transcription is beginning to be appreciated in the muscle physiology and 
pathophysiology. How the ubiquitin proteasome system regulates transcription is well 
established in embryonic stem cells (15), the tumor microenvironment (17), and the heart (14, 
64). The ways in which the UPS post-translationally modifies and regulates transcription by 
directing transcription factors by ubiquitination is emerging through multiple mechanisms. They 
include the degradation of transcription factors by enhancing poly-ubiquitination leading to 
proteasome-dependent degradation. Other mechanisms include ubiquitin playing a role in 
directing the localization of transcription factors (in the case of mono-ubiquitination). Some of 
them are transcription factors part of the signaling pathways involved in the maintenance and 
regeneration of skeletal muscle, including those involved in skeletal muscle atrophy. This review 
focuses on the role of the skeletal muscle ubiquitin ligases, the enzymes giving the UPS 
specificity, in regulating transcription in skeletal muscle so that their broadening diverse roles are 
better appreciated and provide context to thinking about therapeutically targeting them in the 
future. 
 
 
Ubiquitin ligases and their degradation mechanisms 
 
The post-translational modification of proteins via ubiquitination is mediated by three classes of 
proteins in a multistep process. Conjugation of proteins to ubiquitin (Ub) begins with an ATP 
dependent step wherein there is a thioester linkage between the last residue of Ub, i.e., Gly 76 
and Cys residue of the Ubiquitin-activating enzyme, E1. The activated Ub is then transferred to 
the Cys residue of the ubiquitin-conjugating enzyme (E2). The final step is the concurrent 
interaction of the Ub-loaded E2 and ubiquitin protein ligases (E3) resulting in the formation of 
Ub chains on the substrate. When E3s polyubiquitinate their substrate with Lys48-linked 
ubiquitin, the 26S proteasome binds the ubiquitin chains and degrades the substrate. Thus, E3s 
are critical parts of this process, as they are not only responsible for substrate specificity but also 
regulate the efficiency of the process. Ubiquitination of proteins not only targets substrates for 
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degradation but also controls their activity and localization, depending upon the type of Ub-
chains added. On the other hand, there are also deubiquitinating enzymes (DUBs) which catalyze 
the removal of ubiquitin, cellular localization (e.g., mono-ubiquitin), or stability (e.g., non-
lysine48 linked poly-ubiquitin mediated modifications), and also balancing the post-translational 
modification of substrates, thus altering their susceptibility to proteasome-dependent degradation 
(4).  
 
In the pathogenesis of skeletal muscle atrophy, satellite cells play an integral role in recovery and 
regeneration of muscle cells. Once example highlighting the importance of the UPS system and 
the ubiquitin-mediated regulation of transcriptions factors has been described in the regulation of 
satellite cells in skeletal muscle atrophy. The RPT3 (regulatory protein of the 26S proteasome) 
protein is a putative ATPase integral to the 26S proteasome (19). Recent studies have identified 
that depleting RPT3 induced skeletal muscle atrophy and the loss of satellite cells in resting 
skeletal muscle (38). Mice with muscle-specific RPT3 depletion spontaneously develop skeletal 
muscle atrophy starting from three weeks of age and predominant atrophy at four weeks of age 
evidenced by a decrease in myofiber cross-sectional area in gastrocnemius and soleus muscle 
(38). The depletion of RPT3 in mice led to decreased proteasome activity, specifically 
chymotrypsin-like and trypsin-like proteasome activity in the fast-twitch-dominant tibialis 
anterior muscle at two weeks of age (38). Satellite cell-specific Rpt3 conditional knockout (Rpt3-
scKO) mice were generated to deplete Rpt3 specifically in the satellite-cell population (37). 
These mice did not have a significant phenotype as seen by no change in muscle weight or cross-
sectional area in the tibialis anterior muscle a month of tamoxifen treatment in these mice (37). 
Nevertheless, these mice had impaired regeneration due to a defective proliferative stage and 
apoptosis in primary myoblasts isolated from these mice (37). This satellite cell-specific 
proliferation defect could be rectified upon P53 depletion in primary myoblasts isolated from 
these mice (37). 
 
The underlying mechanism of RPT3’s regulation of skeletal muscle atrophy pathogenesis was 
identified to be its regulation of the transcription p53, whereby RPT3 mediated p53 degradation 
through its ATPase activity is critical to proteasome activity (37). Depletion of RPT3 in satellite 
cells led to enhanced p53 expression (37), which then mediated defect in the satellite cell 
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proliferative state and led to apoptosis (37), instead of the needed regeneration to counteract the 
atrophy (37). This example illustrates the critical role of the 26S proteasome’s degradatory 
functions and highlights the importance of upstream regulators of ubiquitination, specifically the 
ubiquitin ligases which give the process specificity. Ubiquitylation and degradation of many 
transcriptional activators at promoter sites (54) is one of the regulators of transcription among 
other regulators like activators, repressive complexes and histones. This review expands this 
basic appreciation of the importance of the proteasome-mediated degradation of transcription 
factors (p53) in satellite cells in skeletal muscle atrophy and investigates how ubiquitin ligases 
specific for transcription factors regulate the body’s resistance to skeletal muscle atrophy. 
 
 
TATA-box binding protein and TATA-box binding protein associated factors 
 
The TATA-box binding protein (TBP) and TATA-box binding protein-associated factors (TAF) 
forms the RNA polymerase II preinitiation complex (PIC) that recognizes the transcription factor 
IID (TFIID) binding to the core promoter of the gene being transcribed. The transcriptional 
activity of MYOD in activated SCs in terms of inducing Myogenin is essential for terminal 
differentiation. This mechanism involved functional interaction with the TFIID complex. Firstly, 
the binding of MYOD to its recognition site is stabilized by TFIID complex/TBP. Eventually, 
MYOD mediates and stabilizes the association of TFIIB to the PIC (33). Thus, TBP levels are 
vital in regulating the transcriptional activity of MYOD.  
 
The TATA-box binding protein (TBP) protein is regulated post-translationally by ubiquitination 
in recent studies. The ubiquitin ligase HUWE1 and deubiquitinase (DUB) USP10 coordinate to 
regulate TBP levels (Figure 2A) (42). Both HUWE1 (HECT, UBA and WWE Domain 
Containing 1), a HECT ubiquitin ligase, and the USP10 DUB are found in proliferating 
undifferentiated myoblasts (42). HUWE1 was found to polyubiquitinate TBP and drive its 
proteasome-dependent degradation (Figure 2A). In undifferentiated myoblasts, the USP10 a 
ubiquitin-specific protease prevents proteasomal degradation of TBP by counteracting HUWE1 
ubiquitination of TBP, thus maintaining stable TBP levels (Figure 2A) (42). The net result of 
this ubiquitin ligase/DUB pairing is the regulation of TBP levels during differentiation (Figure 
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2B). During differentiation, HUWE1 expression increases while USP10 expression decreases, 
favoring the polyubiquitination and subsequent degradation of TBP. The resulting myocyte 
depletion of TBP during differentiation by post-translational degradation via the proteasome is 
an essential mechanism for differentiation (Figure 2B). In contrast, USP10 depletion was not 
sufficient to mediate differentiation (42). The importance of reduced TBP levels in 
differentiation has been reported to be related to TBP’s regulation of MyoD (46). By regulating 
the TBP levels through posttranslational ubiquitination and degradation, the ubiquitin ligase 
HUWE1 and deubiquitinase USP10 play a cohesive role in maintaining TBP levels during 
myogenesis (42). The HUWE ubiquitin ligase also has been reported to directly regulate MYOD 
protein level via mono-ubiquitination and proteasome-dependent degradation (51), which may 
parallel its indirection regulation of MYOD described above (42). Since the role of TBP in 
muscle regeneration has been established in previous studies, in depth understanding of how 
TBP levels are modulated would be important to have a clear understanding about various 
pathways in muscle regeneration.  
 
 
Neural precursor cell-expressed developmentally downregulated gene 4 
 
NEDD4 (Neural precursor cell-expressed developmentally downregulated gene 4) has a role in 
cellular processes involving turnover of membrane-bound channels and receptors associated with 
protein trafficking, endocytosis, virus budding, and transcription. NEDD4, along with its family 
of proteins, has a phospholipid-binding C2 domain, two to four WW domains that recognize 
substrates, and a catalytic domain homologous to the E6-AP C-terminal (HECT) domain (71). 
NEDD4 associates with cellular membranes via its C2 lipid-binding domain, allowing for the 
interaction between the WW domains of NEDD4 and PPXY motifs of its membrane-associated 
protein substrates (39). WWP2 was shown to interact with and monoubiquitinate the membrane-
anchored fragment of NOTCH3, leading to its degradation, possibly via the 
endosomal/lysosomal pathway. As a result, NOTCH signaling activity was reduced (75). 
NOTCH is a transmembrane receptor protein that is sequentially cleaved upon ligand binding, 
releasing its ‘‘activated’’ intracellular domain, which translocates from the cytosol to the nucleus 
to influence transcription. 
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The ubiquitin ligase NEDD4 has recently been implicated in mediating denervation-induced 
atrophy, with NEDD4 depletion leading to muscle mass retention (Figure 3A) (50). Activation 
of NOTCH by its ligands leads to the release and translocation of its intracellular domain 
(NICD) to the nucleus where it interacts with RBP-Jκ (Recombination Signal Binding Protein 
For Immunoglobulin Kappa J Region), a DNA binding protein that activates transcription of Hes 
and Hey which inhibit MyoD gene transcription (Figure 3A) (63). The NICD protein directly 
regulates PAX7 expression through RBP-Jκ to mediate self-renewal rather than differentiation. 
NEDD4 regulates the expression of the transcription factor PAX7, which in turn is responsible 
for myogenin induction (Figure 3A) (53, 70). Evidence for the regulation of Notch by NEDD4 
comes from studies of unloading and denervation of the rat hindlimb, resulting in a significant 
increase in NEDD4 expression in the soleus, plantaris, and gastrocnemius in rats (39). 
Simultaneous with this increased NEDD4 expression, NOTCH1 expression decreased, 
suggesting that NOTCH1 is a NEDD4 substrate that is degraded by the UPS (39). To 
demonstrate this relationship, the expression of a dominant negative NEDD4 in soleus muscles 
was tested in vivo and found to completely reverse the unloading-induced decrease in NOTCH1 
expression (39). When NEDD4 was conditionally increased in C2C12 cells, an increase in 
NOTCH1 ubiquitination was observed, indicating that NOTCH1 was a NEDD4 substrate in 
skeletal muscle atrophy (39).  
 
The mechanism by which PAX7 through NOTCH1 regulates skeletal muscle atrophy may be 
related to its regulation of muscle-derived stem cells (49). For example, NOTCH-activating 
factors from osteosarcoma cells repress myogenesis thereby inducing atrophy (49). Thus, 
NEDD4 mediated reduction in NOTCH signaling leading to the precocious differentiation and 
depletion of SC reservoir thus aggravating atrophy may be one mechanism to consider. PAX7 
regulates skeletal muscle atrophy by regulating the regenerating mechanisms as can be seen by 
cancer cachexia caused due to impaired regulation of PAX7 levels (65).  
 
Subsequent studies reported that NEDD4 modulates PAX7 during early muscle differentiation, 
by depleting PAX7 levels by subjecting it to ubiquitination; conversely, NEDD4 loss results in 
the accumulation of PAX7 (Figure 3B) (16). Transient nuclear accumulation of NEDD4 induced 
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decrease in PAX7 and precocious muscle differentiation, demonstrating that NEDD4 functions 
as a novel PAX7 regulator temporally and spatially controlled to modulate PAX7 protein levels 
and satellite cell fate (16). PAX7 levels were found to be regulated by the proteasome system in 
cells initiating differentiation, but not cells in the proliferating stage. Blocking the proteasome 
was found to increase the levels of PAX7 in differentiating myoblasts, consistent with NEDD4-
mediated degradation of PAX7 (16).  
 
Unexpectedly, the c-terminus domain of PAX7 in differentiating skeletal muscle cells was found 
to be mono-ubiquitinated by NEDD4 (16), which is not generally a signal for the proteasome-
mediated degradation observed in these studies as poly-ubiquitin chains are classically required 
to be recognized by the proteasome ubiquitin receptor subunits (21, 34). Interestingly, mono-
ubiquitination is not an uncommon signal for degradation and has been demonstrated in other 
Pax family members, including PAX3 (12). Preventing the proteasome-dependent degradation of 
PAX3 in satellite cells blocks myogenic progression due to the impaired control of PAX levels 
(41). For myogenic progression to happen after satellite cell activation, PAX3 protein is 
depleted, whereas, whereas no change in PAX7 protein levels. The mechanism by which PAX3 
is depleted during satellite cell activation has been reported to be through “mono-ubiquitination”, 
which facilitates subsequent poly-ubiquitination and degradation by the 26S proteasome (12). 
While PAX7 protein levels do not change during this early stage of myogenesis, PAX7 
degradation is a critical component in later stages of the myogenic process (i.e., differentiation) 
(27). 
 
In addition to the proteasome-dependent mechanism, caspase-3 mediated cleavage also 
contributes to reduced PAX7 levels (30). Counter-acting the proteasome-dependent PAX7 
degradation is the casein kinase 2 (Ck-2) phosphorylation of PAX7, which prevents degradation. 
In addition to this, it was also found that Pax7 phosphorylation directed by CK-2 reduces caspase 
mediated cleavage of PAX7 (22). When casein kinase 2 (Ck-2) phosphorylates PAX7 at S201, 
PAX7 degradation by the proteasome system and caspases is inhibited, thus stabilizing PAX7 
levels (30), which is prominently seen in proliferating cells. The PAX7 protein is also regulated 
by the addition of small ubiquitin-like modifiers (SUMO). SUMOylation is a post-translational 
modification process paralleling ubiquitination involving the conjugation of SUMO instead of 
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ubiquitin. SUMOlyation of PAX7 is also essential in myogenic differentiation as it mediates 
transactivation of PAX7 regulated genes prior to differentiation, as shown in C2C12 cells (45). 
Having a comprehensive understanding of various regulators of PAX7 including its modulation 
by the UPS system will help in developing a holistic understanding of the regulators of PAX7. 
 
 
Thyroid Hormone Receptor Interactor 1 
 
TRIP12 (Thyroid Hormone Receptor Interactor 1), a HECT domain encoding ubiquitin ligase, 
regulates the fiber type switching in adult skeletal muscle myocytes (5). Adult skeletal muscles 
are composed of short-twitch fibers, and fast-twitch fibers, based on various external and internal 
cues and the composition varies in healthy and diseased states (56). At a molecular level, slow-
twitch fibers express myosin heavy chain (MyHC) isoform MyHC-Iβ, Myh7 and use oxidative 
metabolism, whereas the fast-twitch fibers include those expressing MyHC-IIA, MyHC-IIX/D 
and MyHC-IIB, Myh4 which use glycolytic or mixed metabolism (52). The contraction speed of 
fast-twitch fibers is higher than that of slow-twitch fibers and they also differ in their sensitivity 
to calcium and fatigue resistance, among other characteristics (56). Muscle atrophy caused by 
distinct pathophysiological conditions have a distinct effect on the composition of either slow or 
fast-twitch fibers, based on the signaling mechanism by which the atrophic condition is induced. 
Muscle wasting induced by sepsis, cancer cachexia, AIDS, aging, glucocorticoid administration, 
starvation, acute diabetes in the diaphragm, during heart failure, and COPD is characterized by 
the presence of fast-twitch fibers and fast-to-slow fiber type shift (18). On the other hand, muscle 
wasting caused by hand denervation, spinal cord injury, limb immobilization, hindlimb 
suspension in a shortened position, spinal cord injury, bed rest, microgravity and in limb muscles 
during heart failure and COPD are characterized by a shift from slow to fast fiber types. The 
TRIP12 ubiquitin ligase regulates fiber type switching by regulating the expression of the SOX6 
transcription factor (Figure 4), which is critical in enhancing the transcription of fast fiber genes 
such as Myh5 and suppressing the transcription of slow fiber genes such as Myh7 and myogenin. 
 
The TRIP12 HECT domain is the SOX6 substrate recognition module and catalytic domain, 
which mediates SOX6 polyubiquitination, resulting in SOX6 targeting to the 26S proteasome for 
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degradation (Figure 4A) (5). In C2C12 myotubes, TRIP12 or proteasome inhibition was found 
to increase SOX6 protein levels (5). Control of SOX6 by TRIP12 ubiquitination resulted in 
significant changes in the resulting myocyte phenotype. TRIP12 knock-down in C2C12 
myotubes resulted in SOX6 upregulation, a decrease in slow fiber-specific Myh7 and myogenin 
expression and an upregulation of the fast-fiber Myh4 (5). Together these studies demonstrate 
that the TRIP12 ubiquitin ligase regulates the SOX6 protein level, which itself controls the fiber 
type gene expression and phenotype critical to the alterations seen in different types of skeletal 
muscle atrophy (Figure 4B). In this way, Trip-12 mediated fiber-type switching could 
potentially alter the work-load capacity and function in skeletal muscle atrophy, although this 
hypothesis has not directly been tested to date (5). The SOX6 protein is also regulated by the 
addition of small ubiquitin-like modifiers (SUMO). Recent studies have reported that SOX6 is 
modified in vivo by SUMO on two distinct lysine residues in a process dependent upon the E2 
conjugating UBC9 enzyme, involving the addition of the SUMO2 isoform, resulting in the 
enhancement of SOX6 activity (24). The significance of SOX6 SUMOlyation in skeletal muscle 
has not been tested direct to date but may offer complementary regulatory mechanisms to 
TRIP12 since both SUMO and Ubiquitin bind lysine residues and have been reported to compete 
in other biological systems.  
 
 
TNF Receptor Associated Factor 7 
 
Tumor necrosis factor-associated factor (TRAF) proteins are cytosolic protein functioning as 
signal transduction pathways for receptors. TRAF7 (TNF Receptor Associated Factor 7) is a 
member of the tumor necrosis factor (TNF) receptor-associated factors. TRAF7 activates several 
signaling pathways and mediates cellular processes like proliferation, differentiation, and 
apoptosis. TRAF7 is unique among TRAFs as the only member to physically associate with IκB 
kinase/NF-κB essential modulator (NEMO) and the p65 (RelA/p65) member of the NF-κB 
transcription factor family (Figure 5) (74). TRAF7 is composed of an N-terminal RING domain 
with an adjacent zinc-domain and seven WD40 repeats at the carboxy terminal (73). Studies of 
TRAF7 in cancer cells identified that the TRAF7 ubiquitin ligase poly-ubiquitinates NEMO and 
p65 with Lysine 29-linked chains which promote their degradation (Figure 5A) (74). In addition 
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to inhibiting NF-κB signaling, TRAF7 appears to promote AP-1 transcriptional activity (74) and 
the C/EBP-homologous protein (CHOP) transcriptional activity (66). While considerable 
information about TRAF7’s regulation of NF-κB in cancer cells is known, its role in myocyte 
differentiation suggests that TRAF7’s role may go beyond NF-κB signaling. 
 
TRAF7 regulates myoblast differentiation through its activity as a ubiquitin ligase. The RING 
domain of TRAF7 promotes Lys-29-linked mono-ubiquitination of NEMO (IKKγ) (Figure 5C) 
(60). This leads to activation of the NF-κB signaling which transcriptionally regulates cyclin D1 
and mediates myoblast proliferation (Figure 5D) (31). MYOD1 is one of at least four 
transcription factors that regulate myocyte differentiation, in addition to MYF5, myogenin, and 
MRF4 (57). Chromatin IP (ChIP) studies in C2C12 myoblasts identified that MYOD directly 
regulates the expression of ubiquitin ligase, including Traf7 (60). When MYOD is depleted, a 
reduction of Traf7 gene expression results, implicating MYOD regulation of the NF-κB pathway 
via Traf7. In contrast, when TRAF7 is reduced in C2C12 myoblasts, significantly reduced NF-
κB transcriptional activity is observed in luciferase reporter assays, consistent with TRAF7’s 
support of NF-κB activity by regulating the p65 subunit (60). Depletion of TRAF7 reduces p65 
nuclear translocation, thereby diminished NF-κB mediated cyclin D1 transcription leading to 
premature differentiation (Figure 5E) (60). However, the NF-κB dependent cyclin D1 activation 
was reduced in the later stages of myogenesis wherein the cells moved from a proliferating state 
to a differentiating state (48).  
 
 
Up-Frameshift Suppressor 1 Homolog 
 
Up-Frameshift Suppressor 1 Homolog (UPF1) is an RNA helicase initially found to be a key 
component in the nonsense-mediated RNA decay (NMD) pathway, and later reported to have a 
RING like domain of UPF1 which has ubiquitin ligase activity (37). Interestingly, the UPF1 
ubiquitin ligase activity was found to regulate myogenesis by regulating the MYOD transcription 
factor (23). UPF1 regulates MYOD levels both degrading mRNA encoding MYOD and also 
directly by ubiquitinating the MYOD protein and targeting it for proteasome-dependent 
degradation (23). This was confirmed by studies wherein depleting RING domain of MYOD did 
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not reduce MYOD protein (23). Blocking UPF enhanced myogenesis in myoblasts due to 
sustained MYOD levels (23). UPF1 thus was found to play a critical role in myogenesis process 
by regulating MYOD’s targeted proteasome-mediated degradation, a key transcription factor in 
myogenesis.  
 
 
Mouse double minute 2 homolog 
 
Mouse double minute 2 homolog (MDM2) is a RING finger family ubiquitin ligase that 
regulates the differentiation of myoblasts via its post-translational regulation of p53 via 
ubiquitination (27). The role of p53 in myocyte differentiation is well established in previous 
studies. Using an unbiased approach, studies of satellite cell-derived myoblast transcriptional 
regulation found that p53 is a key regulator of myoblast quiescence (25). Specifically, when 
cultured myoblasts are activated and proliferate, an upregulation of p53 is seen and cells fail to 
differentiate (25). The sustained p53 increases in myoblast subpopulations of activated and 
proliferating cells not only hinders differentiation of these cells after their exit from cell cycle, it 
also leads to their quiescence (25). P53 binds to myogenin and represses its transcription, thus 
preventing the differentiation of myoblasts under genotoxic stress (67). It was also found that 
p53 expression is increased during atrophic conditions and plays an important role during 
atrophic conditions (26). 
 
Satellite cells express CCAAT/Enhancer-binding protein β (C/EBPβ) that maintains them in their 
quiescent state by stimulating PAX7 expression and by triggering decreased MYOD protein 
expression (Figure 6A). Recent studies have identified that increased MDM2 expression 
accompanies the loss of C/EBPβ proteins, which led to the hypothesis that MDM2 interacts with 
and ubiquitinates C/EBPβ (Figure 6B) leading to its degradation in a proteasome-dependent 
manner (Figure 6C) (27). Consistent with this mechanism of action, knock-down of MDM2 
expression in myoblasts resulted in increased C/EBPβ and the blockade of myogenesis; similarly 
knockdown of MDM2 in primary myoblasts resulted in the inability of muscle regeneration 
when grafted into cardiotoxin-injured muscle (27). Since the differentiation defect seen with 
increased MDM2 could be rescued by inhibiting the proteasome or by increasing C/EBPβ, a 
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mechanism by which MDM2 regulates myogenesis by degrading C/EBPβ has been proposed 
(Figure 6D) (27). Studies demonstrating the interaction between MDM2 and C/EBPβ by co-IP 
and ubiquitination assays illustrate this mechanism as a pivotal regulator of myogenic 
differentiation and regeneration in vivo (27).  
 
 
Atrogin-1/Muscle Atrophy F-box (MAFbx) 
 
During myocyte differentiation, the Atrogin-1 ubiquitin ligase regulates differentiation by 
targeting MYOD1 for ubiquitination and 26S proteasome-dependent degradation, in addition to 
regulation of other transcription factors critical for muscle differentiation (40). Atrogin-1 is a 
muscle specific ubiquitin ligase implicated in skeletal muscle atrophy (9). Atrogin-1 has been 
upregulated in skeletal muscle atrophy induced by glucocorticoids, denervation, spinal cord 
transection, hind limb suspension, immobilization, renal failure, diabetes, long-term mechanical 
ventilation, Cachexia, HIV, COPD, lipopolysaccharide (LPS)-induced changes in muscle 
catabolism, aging, alcohol, spinal muscle atrophy, heart failure, space flights, thermal injury, 
cytokine mediated muscle loss, smoking, myositis, acute lung injury, statins, arthritis, hypoxia, 
knee arthroplasty, pulmonary arterial hypertension (8). Previous studies have reported that 
increased Atrogin-1 in atrophy contributes to the degradation of the myofibrillar proteins in the 
cytoplasm (Figure 6E) (29). In myotubes undergoing starvation mediated atrophy, reduction in 
MyoD was observed upon activation of Atrogin-1 and its translocation to the nucleus (Figure 
6F). Conversely, shRNA knock-down of Atrogin-1 blocked MYOD proteolysis associated with 
muscle atrophy (40). Additionally, mutant MYOD (K113R), which lacked the Atrogin-1 
ubiquitination site, prevented atrophy of primary mouse myotubes and skeletal muscle fibers in 
vivo illustrating that Atrogin-1 plays a critical role in atrophy as a regulator of MYOD via poly-
ubiquitin-mediated degradation during atrophic conditions. 
 
 
PRAJA1 
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The PRAJA1 ubiquitin ligase promotes skeletal muscle myogenesis through its regulation of the 
EZH2 transcription factor upon P38α activation (Figure 7) (20). In myogenesis, PRAJA1 is first 
identified in the cytoplasm of MYOD-positive cells three days after cardiotoxin-induced muscle 
damage (20). The expression of PRAJA1 itself is increased during muscle cell differentiation 
(Figure 7A) (20). At later stages of the regeneration process, PRAJA1 re-localizes to the nucleus 
of the MYOD-positive cells and the number of PJA1-positive cells begins to decline (20). The 
cytoplasm-to-nuclear changes suggest the PRAJA1 may have different targets in proliferating 
myoblasts when they are induced to differentiate (20). Recent bioinformatics analysis predicted 
that PRAJA1 would interact with Enhancer of zeste homologue 2 (EZH2), which has been 
independently shown to be true experimentally (20). In skeletal muscle progenitor cells, EZH2 
maintains muscle gene chromatin in a repressive conformation with the catalytic subunit of 
Polycomb Repressive Complex 2 (PRC2) (20). EZH2’s gene repression plays a vital role in the 
satellite cell retention and proliferative phase of myogenesis, whereas in differentiating 
myoblasts the EZH2 levels are depleted (65). In C2C12 cells depleting PRAJA1 blocks terminal 
differentiation, thus indicating the vital role of PRAJA1 in myogenesis (20).  
 
A recent publication reported that the P38α kinase promotes the EZH2 by phosphorylating it at 
the threonine 372 position (Figure 7B) (20). In addition, both biochemical and genetic studies 
provided evidence that MYOD-induced PRAJA1 expression regulates EZH2 levels when P38α 
is activated (20). EZH2-associated proteins were then found to be targets of the PJA1-induced 
ubiquitination in muscle cells (20), consistent with previous studies using a cell-free system (72). 
The resulting EZH2 poly-ubiquitinated protein is then degraded in a proteasome-dependent 
manner (Figure 7C) (20). When EZH2 degradation is blocked in proliferating myocytes by 
decreasing PRAJA1 levels, EZH2 stays localized in the cytoplasm and has lower activity 
towards un-phosphorylated EZH2 (20). Together these studies demonstrate that p38α signaling 
is necessary to induce the PJA1/EZH2 interaction, whereby EZH2 is ubiquitinated and degraded 
during satellite cell differentiation. 
 
 
Summary 
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Post-translational regulation is emerging as a critical regulator of skeletal muscle repair and 
regeneration in physiological and pathophysiological states. In this review, we discuss the role of 
both ubiquitin ligases (HUWE1, NEDD4, TRIP12, TRAF7, UPF1, MDM2, ATROGIN-1, 
PRAJA1) and deubiquitinase (USP10) in regulating multiple transcription factors known to 
control myogenesis, including the regulation of muscle fiber type switching in differentiated 
myocytes in skeletal muscle atrophy (Table 1). TRAF7, HUWE1, PRAJA1, and MDM2 regulate 
the transition of quiescent satellite cells to activated, proliferating satellite cells by regulating the 
NF-kB, TBP, EZH2, and C/EBPβ transcription factors, respectively, via ubiquitination (Figure 
8A-C). Interestingly, the HUWE and PRAJA1 ubiquitin ligases further regulate SC 
differentiation in concert with NEDD4 and a yet to be identified E3, which regulates the PAX7 
and PAX3 transcription factors (Figure 8D-E). In addition, NEDD4 temporally and spatially 
mediates different stages of myogenesis by independently inhibiting NOTCH signaling (Figure 
8F). Both Atrogin-1, UPF-1, and HUWE1 ubiquitin ligases direct the post-translational 
degradation of MYOD and are altered accordingly to allow MYOD expression during 
differentiation (Figure 8G). The TRIP12 ubiquitin ligase has an interesting role in serving as the 
focal point in slow-fast twitch fiber transition and vice-versa in different kinds of atrophies 
(Figure 8H). Together these findings illustrate an array of examples by which ubiquitin ligases 
regulate transcription factors critical to myogenesis and likely are only a small sample of all the 
ubiquitin ligases involved. 
 
Impaired myogenesis is seen in several diseases like cachexia, muscle dystrophy, neuromuscular 
junction degeneration (2, 35, 43). Myogenesis capabilities are impaired upon aging and there 
have been several therapeutic options evolved to rejuvenate satellite cell function and activity in 
order to improve muscle regeneration. Apart from therapeutic strategies for dealing with aging, 
simple changes in lifestyle like regular exercise, low-calorie diet have been shown to have 
profound impact in improving the satellite cell number and activity (6). Similarly, atrophy has 
also been shown to be reversed by regular exercise and rehabilitation. Myogenesis is also 
blocked in rhabdomyosarcoma (RMS), a pediatric soft tissue sarcoma and it involves modulation 
of several transcription factors like Pax3, EZH2, Notch, NF-κB etc., which were discussed in this 
review (68). Differentiation therapy is one of the most possible therapeutic options being 
considered for RMS, in addition to targeting MYOD and MYF5 (59). There are several examples 
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in the literature indicating how therapeutic targets are feasible at various stages of the myogenic 
lineage. The atrophy condition indicated by the extent of muscle mass present is an 
amalgamation of protein degradation and myogenesis. Several E3s including Atrogin-1, NEDD4, 
TRAF6, TRIM32, TRIM72, USP10 either directly or indirectly impact the transcription factors 
which are key to myogenic progression in addition to regulating other signaling mechanisms that 
mediate myogenesis (7). Targeting the proteasome system has been a prominent therapeutic 
strategy for cancer cachexia (3) and further understanding of the intricate mechanisms regulated 
by the proteasome in mediating atrophy is critical. For example, MDM2 which degrades C/EBPβ 
discussed in this paper could be another possible therapeutic target in cancer cachexia, as it was 
shown earlier that C/EBPβ inhibits myogenesis (47). The possibility of specific E3 being 
assessed as the therapeutic target for the muscle wasting diseases varies, as each of the diseases 
encompassing atrophy is regulated by distinct signaling mechanisms(s). 
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Table 1. Summary of ubiquitin ligases regulating transcription in skeletal muscle. Abbreviations: HUWE1: HECT, UBA 
And WWE Domain Containing 1, E3 Ubiquitin Protein Ligase; MDM2, Mouse double minute 2 homolog; NEDD4: Neural 
precursor cell-expressed developmentally downregulated gene 4; TRIP12: Thyroid Hormone Receptor Interactor 12; TRAF7: 
TNF Receptor Associated Factor 7; UPF1, Up-Frameshift Suppressor 1 Homolog; USP10: Ubiquitin Specific Peptidase 10. 
Ubiquitin 
ligase 
Substrate Known E3 – Substrate Interaction System E3 / 
Substrate 
Tested 
Role in Skeletal 
Muscle Atrophy 
Refere
nces 
 
 
HUWE1 
(E3) 
 
 
 
USP10 
(DUB) 
 
 
 
TATA-
binding 
protein 
(TBP) 
HUWE1 targets TBP for K48-linkedin 
ubiquitination and proteasome-mediated 
degradation 
 
USP10 is a de-ubiquitinase (DUB) that removes 
poly-ubiquitin from TBP to counteract HUWE1 
ubiquitination 
 
Increase in HUWE1 and decrease in USP10 
leads to depletion of TBP in differentiating cells 
 
C2C12 
myoblasts 
and myotubes 
 
 
 
C2C12 
myoblasts 
 
Reduction in TBP levels 
which regulate MyoD 
during terminal 
differentiation 
 
 
Increased HUWE1 (or 
decreased DUB) decrease 
TBP protein levels and 
block differentiation and 
myogenic progression.  
 
(42) 
 
 
 
 
 
(46) 
 
 
 
 
 
NEDD4 
(E3) 
 
 
 
PAX7 
 
 
 
 
 
 
NOTCH 
 
NEDD4 and PAX7 interact during early muscle 
differentiation 
 
 
PAX7 ubiquitinated and degraded 
 
Intracellular domain of activated NOTCH 
translocates to the nucleus wherein it 
upregulates PAX7. NEDD4 blocks translocation 
of NCID to the nucleus 
Adult primary 
myoblasts and 
isolated 
myofibers 
 
C2C12 cells 
 
Primary 
myoblasts 
from hindlimb 
skeletal 
muscles 
 
 
Promotes differentiation 
 
 
 Promotes differentiation 
 
Down-regulated in 
denervation and 
unloading induced 
atrophy 
 
 
(16) 
 
 
 
 
(39) 
 
TRIP12 
(E3) 
 
SOX6 
 
TRIP12 interacts with and polyubiquitinates 
SOX6 for proteasome-dependent degradation 
 
C2C12 
myotubes 
Focal-point in mediating 
the transition between 
fast-slow fiber and slow-
fast fiber. 
 
 
(5)  
 
 
 
TRAF7 
(E3) 
 
 
NEMO 
TRAF7 binds IκB kinase/NF-κB essential 
Modulator (NEMO) and the p65 NF-κB 
transcription factor to promote Lys-29 
polyubiquitination of NEMO targeting 
lysosomal degradation of both proteins (74). 
 
C2C12 
myoblasts 
and myotubes 
Essential in myogenesis 
during the proliferation 
phase 
 
Prevents precocious 
differentiation 
 
 
(60) 
 
UPF1 
(E3) 
 
MYOD 
 
UPF1 poly-ubiquitinates MYOD and targets for 
proteasome-dependent degradation 
54-1 and 
MB135 
myoblasts 
 
Inhibits myogenesis 
 
(23) 
 
 
 
 
MDM2 
(E3) 
 
 
 
 
C/EBPβ 
 
 
 
MDM2 interacts with, ubiquitinates, and targets 
C/EBPβ for 26S proteasome dependent 
degradation and can alter C/EBPβ-mediated 
satellite cells in the quiescent state 
C2C12 cells 
 
 
 
 
Myoblasts 
 
MDM2 degrades p53 
thus enabling 
differentiation after exit 
from cell cycle  
 
MDM2 knockdown in 
primary myoblasts results 
in the inability of muscle 
regeneration when 
grafted into cardiotoxin-
injured muscle 
 
 
 
 
 
(25, 27) 
 
ATROGIN-1 
(E3) 
 
 
MYOD 
 
Atrogin-1 translocates to the nucleus during 
atrophic conditions and depletes MYOD levels 
 
C2C12 
myotubes and 
in cellulo 
C2C12 
myoblasts 
Mediates atrophic 
conditions by degrading 
MYOD proteins in a 
proteasome-dependent 
manner 
 
 
(40) 
 
PRAJA1 
(E3) 
 
EZH2 
PRAJA1 poly-ubiquitinates EZH2, targeting it 
for proteasome-dependent degradation, resulting 
in a shift from proliferation to differentiation 
 
C2C12 cells 
Mediates terminal 
differentiation 
 
(20) 
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Figure legends. 
 
Figure 1. Stem cell renewal and the molecular regulation of muscle cell differentiation 
(myogenesis). Skeletal muscle satellite (stem) cells can divide asymmetrically into differentiated 
cells and renew (A) with different stem cell populations asymmetrically dividing, with some 
satellite cells dividing asymmetrically and other just differentiative (B). In generally, satellite cell 
levels of PAX7 are low in the asymmetrically dividing cells (A), while higher in the cells that 
differentiate (C). Upon myogenic stimuli (e.g., contractile activity, direct/indirect myocyte 
damage), PAX7 expressing quiescent cells (C) have increased expression of muscle regulatory 
gene, (D) MYOD thus activating the cells and leading to proliferation (D). At this stage, the cells 
can return to quiescent state by losing MYOD (E) or differentiate (F) by losing PAX7 which 
increases expression of myogenin. G. The terminally differentiated cells fuse to form myofibers. 
 
Figure 2. Regulation of TATA-box binding protein (TBP) levels by the ubiquitin 
proteasome system. (A) The HUWE1 ubiquitin ligase polyubiquitinates TBP4 and targets it for 
recognition by the 26S proteasome, which degrades the protein. The deubiquitinase (DUB) 
USP10 removes TBP polyubiquitin chains to counteract this targeted degradation. (B) In 
proliferating myoblasts, HUWE1 ubiquitin ligase activity (polyubiquitination) is counteracted by 
USP10 DUB removing TBP polyubiquitin chains resulting in the stabilization of TBP levels. 
C2C12 myoblasts induced to undergo differentiation have reduced TBP levels resulting from an 
increase in HUWE1 levels and a decrease in USP10, resulting in the enhanced ubiquitin-
mediated proteasome degradation of TBP. TBP, TATA-box binding protein; UPS, ubiquitin 
proteasome.  
 
Figure 3. NEDD4 mediated transcriptional regulation in myogenesis. (A) During the 
proliferation phase of myogenesis, NEDD4 regulates myogenesis by its effects on NOTCH 
signaling. NEDD4 polyubiquitinates NCID (NOTCH) preventing its nuclear translocation and 
activation of the RBP-Jκ (Recombination Signal Binding Protein For Immunoglobulin Kappa J 
Region) transcription factor. By inhibiting RBP-Jκ, NEDD4 prevents the transcription of 
proteins critical to myocyte differentiation. Recent studies have demonstrated that increased 
NEDD4 expression leads to precocious myocyte differentiation by inhibiting Hes and Hey, 
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allowing the enhanced myogenin expression/activity. (B) Myogenic stimuli enhances NEDD4 
translocation to the nucleus where it ubiquitinates PAX7, targeting it for 26S-dependent 
proteasome degradation. Since PAX7 inhibits myogenin (Panel A), increased myogenin and 
myocyte differentiation results from enhanced nuclear NEDD4 activity.  
 
Figure 4. The TRIP12 ubiquitin ligase regulates muscle fiber type switching through its 
regulation of the SOX6 transcription factor. (A) TRIP12 polyubiquitinates SOX6 which 
enhances SOX6 degradation via the 26S proteasome. By blocking SOX6 activity, enhanced 
expression of Myh7 (enhancing the slow-twitch muscle phenotype) and concurrent decrease in 
Myh5 expression (decreasing the fast-twitch muscle phenotype) results. In contrast, deletion of 
TRIP12 (leading to enhanced SOX6 expression) enhances a fast-twitch muscle phenotype. (B) 
Muscle fiber type switches are typical in skeletal muscle atrophy. The significance of TRIP12’s 
regulation of SOX6 stems from its potential role in skeletal muscle atrophies characterized by 
slow-twitch fibers (left) or fast-twitch fibers (right).  
 
Figure 5. Proliferating myocytes exit the cell cycle during differentiation that is dependent 
upon the TRAF7 ubiquitin ligase involved in down-regulating Cyclin D1 expression/ 
activity. (A) TRAF7 ubiquitin ligase polyubiquitinates NEMO and targets it for 26S 
degradation. When the NEMO component of the inhibitor of kB kinase (IKK) complex is 
degraded. (B) In the studies described in the body of the text, the MYOD transcription factor 
depletes TRAF7 transcription and protein expression, leading to inactivation of the NF-κB 
activity and reduced cyclin D1, leading to exit from cell-cycle and thereby driving the cells from 
proliferation to differentiation stage. (C) The IKK complex is released from NEMO and can then 
phosphorylate the IκB protein (inhibitory kappa B protein) complexed with the p65 and p50 NF-
κB subunits. This results in degradation of the IκB protein, allowing the p65/p50 NF-κB 
transcription factor to (D) translocate to the nucleus and regulate gene transcription, including 
Cyclin D1 critical to cell cycle and proliferation of cells. (E) Summary of TRAF7 activity in 
myocyte differentiation.  
 
Figure 6. The MDM2 ubiquitin ligase activity poly-ubiquitinates C/EBPβ targeting it for 
proteasome-dependent degradation. (A) In the undifferentiated state, C/EBPβ supports the 
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expression of Pax7 and inhibits MYOD expression. (B) The MDM2 ubiquitin ligase can poly-
ubiquitinate C/EBPβ targeting it for degradation by the 26S proteasome resulting in (C) 
enhanced MYOD transcription secondary to the loss of C/EBPβ activity and (D) myogenic 
induction (differentiation). (E) During atrophic conditions, Atrogin-1 expressed is increased 
which in turn degrades the myofibrillar protein. (F) In addition, Atrogin-1 also translocates to the 
nucleus wherein it ubiquitinates and degrades MYOD, thus blocking differentiation, as described 
in more detail in the text.  
 
Figure 7. PRAJA1’s ubiquitin ligase activity regulates differentiation by targeting 
phosphorylated EZH2 for degradation by the 26S proteasome. (A) PRAJA1 ubiquitin ligase 
expression is low during satellite cell proliferation and increases during differentiation. (B) 
During differentiation, the P38 MAPK phosphorylates the EZH2 transcription factor, which is 
then recognized by the PRAJA1 ubiquitin ligase. (C) PRAJA1 then poly-ubiquitinates EZH2, 
targeting it for degradation by the 26S proteasome. (D) Since EZH2 drives the transcription and 
expression of Praja1, PRAJA1-mediated degradation of EZH2 effectively forms a negative 
feedback which decreases EZH2 expression. 
 
Figure 8. Summary of the role of ubiquitin ligase regulation of transcription factors during 
myocyte differentiation (myogenesis). (A) TRAF7’s ubiquitin ligase activity activates NF-κB 
signaling via NEMO ubiquitination to support the SC proliferation. (B) The TBP transcription 
factor is regulated by the HUWE1 ubiquitination ligase and the USP1 deubiquitinase to maintain 
stable levels of TBP during proliferation stage. However, in the later stages there is an increase 
in Huwe1 and decrease in USP1 levels thereby leading to reduced TBP levels which is essential 
for differentiation. (C) The PRAJA1 and MDM2 ubiquitin ligases are increased during 
proliferation and poly-ubiquitinate and degrade the EZH2 and C/EBPβ, respectively, effectively 
releasing the inhibition on proliferation. PRAJA1 levels are tightly regulated throughout the 
myogenic lineage, which in a positive feedback loop mechanism degrades phosphorylated 
EZH2, a vital gene regulator in myogenesis. (D) The NEDD4 ubiquitin ligase inhibits PAX7 
protein levels during myogenesis while and (E) a yet to be identified ubiquitin ligase (E3?) 
inhibits the PAX3 transcription factor. NEDD4 leads to PAX7 depletion by ubiquitination and 
26S proteasome degradation. (F) NEDD4 also inhibits Notch signaling to accelerate 
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differentiation in an unrelated mechanism. (G) The ubiquitin ligases Atrogin-1 and UPF-1 
independently degrade MYOD, thereby modulating MYOD levels essential for differentiation. 
(H) The TRIP12 ubiquitin ligase regulates SOX6 protein levels to control the transition of fast-
twitch fibers to slow-twitch fibers. This is an original figure based on the synthesis of the data 
discussed throughout this review. *Enhances MyoD transcription; **Ubiquitination/26S 
Proteasome-dependent Degradation; # Mono-ubiquitination and degradation; E3?=yet to be 
identified ubiquitin ligase. 
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